Anakinra, a recombinant IL-1 receptor antagonist (IL-1Ra) inhibits both IL-1α and IL-β and has shown efficacy in pustular psoriasis and deficiency of IL-1 receptor antagonist (DIRA) variant (49). Here, IL1A is linked to pustular psoriasis.